0
Cardiothoracic Surgery |

The Hilar Stage IB-IIB Non-small Cell Lung Cancer: Differential Morbidity, Mortality, and Outcomes Between Lobectomy and Pneumonectomy

Matthew Schuchert*, MD; Ryan Macke, MD; Ghulam Abbas, MD; Andre Pitanga, MD; Joshua Landreneau, BS; Omar Awais, DO; Arjun Pennathur, MD; Peter Ferson, MD; Neil Christie, MD; James Luketich, MD; Jill Siegfried, PhD; David Wilson, MD; Rodney Landreneau, MD
Author and Funding Information

University of Pittsburgh Medical Center, Pittsburgh, PA


Chest. 2012;142(4_MeetingAbstracts):51A. doi:10.1378/chest.1390665
Text Size: A A A
Published online

Abstract

SESSION TYPE: Thoracic Surgery II

PRESENTED ON: Tuesday, October 23, 2012 at 04:30 PM - 05:45 PM

PURPOSE: Hilar tumors present significant surgical and oncological challenges, particularly in cases where pneumonectomy may be required. Nonetheless, tumors with clinical N0 status mandate surgical consideration. Our objective was to evaluate the clinical outcome of patients undergoing pneumonectomy compared with lobectomy (with or without bronchoplasty) for clinical stage IB-IIB lung cancers.

METHODS: 253 patients (60 pneumonectomies, 70 sleeve resections, 123 lobectomies) with clinical stage IB-IIB NSCLC based on CT radiographic hilar involvement were evaluated. Mean tumor size was 4.7 cm. Outcome variables included morbidity, mortality, recurrence and survival. Comparisons between groups were performed utilizing the t-test and Fisher’s exact test. Overall and recurrence-free survival estimates were performed utilizing the Kaplan-Maier method.

RESULTS: The pneumonectomy group was younger than the sleeve resection (63.4 vs. 66.0, p=0.15) and lobectomy groups (63.4 vs. 68.4, p=0.001), and were more commonly of male gender (p=0.020). Perioperative mortality was higher in the pneumonectomy group at both 30 (6.7% vs. 1.4% vs. 0.8%) and 90 (13.3% vs. 5.7% vs. 2.4%) days when compared to sleeve resection and lobectomy. Mean follow-up was 28.7, 26.6 and 31.6 months for pneumonectomy, sleeve resection and lobectomy, respectively. Recurrence-free survival was similar between groups (Pneumonectomy - 26% vs. Sleeve Resection - 34% vs. Lobectomy - 44%), though there was a trend favoring lobectomy [p>0.077]. Pneumonectomy was associated with reduced overall survival when compared to lobectomy (30% vs. 40% at 5 years, p=0.040). An increased rate of tumor upstaging was observed in the pneumonectomy patients (30%) when compared to sleeve resection (22.8% and lobectomy (22.0%). By comparison, peripheral Stage IB-IIB tumors (n=307) resected at our institution during this same time period were associated with a significantly increased survival (55% vs. 33% at 5 years, p=0.026).

CONCLUSIONS: Large, hilar, clinically N0 malignancies have differential outcomes unique to their anatomic location, especially when compared to more peripheral tumors. However, this group has a higher perioperative mortality and oncologic risk of recurrence regardless of procedure performed.

CLINICAL IMPLICATIONS: Mature surgical expertise and judgment is required to promote the appropriate use of lobectomy or sleeve resection rather than reflexively employing pneumonectomy for hilar tumors, although this approach may be necessary for selected patients.

DISCLOSURE: The following authors have nothing to disclose: Matthew Schuchert, Ryan Macke, Ghulam Abbas, Andre Pitanga, Joshua Landreneau, Omar Awais, Arjun Pennathur, Peter Ferson, Neil Christie, James Luketich, Jill Siegfried, David Wilson, Rodney Landreneau

No Product/Research Disclosure Information

University of Pittsburgh Medical Center, Pittsburgh, PA

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543